Health Catalyst vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
$307M revenue 2024 (up from $296M 2023); $316M TTM Jun 2025; $26M adjusted EBITDA; 100M+ patient records; expects double-digit growth 2025; low-20s net new platform clients 2024; healthcare analytics leader
About
Health Catalyst is a healthcare data and analytics company founded in 2008 in Salt Lake City, Utah, built on the mission of being a catalyst for massive, measurable, data-informed improvement in the health of humanity. The company's core technology — the Health Catalyst Data Operating System (DOS) — provides healthcare organizations with a cloud-based data platform that aggregates clinical, financial, and operational data from disparate source systems into a unified analytics environment designed specifically for the complexity of healthcare data.\n\nHealth Catalyst serves 40+ health systems and hundreds of hospitals, offering analytics applications, embedded data science teams, and technology-enabled services that help organizations improve quality outcomes, reduce costs, and optimize operations. Its suite includes applications for perioperative efficiency, population health management, sepsis surveillance, and financial analytics. The company differentiates through a unique Tech-Enabled Managed Services model, embedding data scientists alongside health system teams to ensure analytics drive measurable operational change rather than sitting unused.\n\nHealth Catalyst generated $307M in revenue in 2024, up from $296M in 2023, with $26M in adjusted EBITDA and a database of over 100 million patient records. As a publicly traded company (HCAT), it has built one of the largest healthcare-specific analytics platforms in the US. With regulatory pressure, value-based care contracts, and margin compression intensifying across health systems, Health Catalyst's integrated data platform and domain expertise position it as a strategic partner for health systems pursuing data-driven operational transformation.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.